地舒单抗对低骨密度患者肌肉表现的有益影响:一项回顾性倾向评分匹配研究
该回顾性倾向评分匹配队列研究纳入150例骨量减少或骨质疏松患者,比较基础治疗、双膦酸盐和地舒单抗对上下肢肌肉表现的影响。平均随访17.6±9.0个月后,地舒单抗组和双膦酸盐组握力均较维生素D组显著增加,地舒单抗组椅子起立测试力较双膦酸盐组显著增加。作者认为地舒单抗可能优于其他骨质疏松治疗用于低骨密度且肌肉力量差的患者。
要点
- 地舒单抗组和双膦酸盐组握力较维生素D组显著增加,维生素D组为-6.1±10.2%。
- 地舒单抗组椅子起立测试力较双膦酸盐组显著增加(p=0.03)。
- 骨密度和骨代谢参数变化与肌肉表现变化无关。
核心结论
- 地舒单抗使上下肢肌肉力量增加,提示其相比双膦酸盐具有全身性而非部位特异性效应。
- 基于这些发现,作者认为在低骨密度且肌肉力量差的患者中,地舒单抗可能优于其他骨质疏松治疗。
研究设计与样本
- 回顾性、倾向评分匹配(性别、年龄、BMI、随访时间)队列研究,纳入150例骨量减少或骨质疏松患者,接受基础治疗(n=60)、双膦酸盐(n=30)或地舒单抗(n=60)治疗。
- 所有患者在基线和随访时接受肌肉骨骼评估,包括DXA、实验室骨代谢参数、握力和椅子起立测试机械图。
- 计算平均年百分比变化并在研究组间比较。
主要发现
- 平均随访17.6±9.0个月后,地舒单抗组(p<0.001)和双膦酸盐组(p=0.001)握力较维生素D组显著增加(维生素D=-6.1±10.2%;双膦酸盐=+0.8±8.2%;地舒单抗=+5.1±25.5%)。
- 地舒单抗组椅子起立测试力较双膦酸盐组显著增加(维生素D=+5.8±12.7%;双膦酸盐=+0.9±8.6%;地舒单抗=+8.2±14.4%;地舒单抗 vs 双膦酸盐 p=0.03)。
- 骨密度变化和骨代谢参数变化均与肌肉表现变化无关。
临床怎么用
- 作者认为,在低骨密度且肌肉力量差的患者中,地舒单抗可能优于其他骨质疏松治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study examined the effects of denosumab compared to bisphosphonates and vitamin D alone on muscle performance in patients with low BMD. While grip force improved in both the denosumab and bisphosphonate group, a superior increase in chair rising test force was observed in the denosumab group. INTRODUCTION: The aim of this study was to investigate the effect of the anti-resorptive agent denosumab (Dmab) on upper and lower limb muscle performance compared to bisphosphonate (BP) treatment and vitamin D supplementation alone (i.e., basic therapy) in patients with low BMD. METHODS: This retrospective, propensity score-matched (sex, age, BMI, follow-up time) cohort study included 150 osteopenic or osteoporotic patients receiving basic (n = 60), BP (n = 30) or Dmab (n = 60) therapy. All patients underwent a musculoskeletal assessment at baseline and follow-up, including DXA, laboratory bone metabolism parameters, grip force, and chair rising test mechanography. Mean annual percentage changes were calculated and compared between study groups. RESULTS: After a mean follow-up period of 17.6 ± 9.0 months, a significantly higher increase in grip force in both the Dmab (p < 0.001) and BP group (p = 0.001) compared to the vitamin D group was observed (vitamin D = - 6.1 ± 10.2%; BP = + 0.8 ± 8.2%; Dmab = + 5.1 ± 25.5%). The Dmab group showed a significantly higher increase in chair rising test force compared to the BP group (vitamin D = + 5.8 ± 12.7%; BP = + 0.9 ± 8.6%; Dmab = + 8.2 ± 14.4%; Dmab vs. BP p = 0.03). Neither the changes in BMD nor in bone metabolic parameters were associated with changes in muscle performance. CONCLUSION: Dmab resulted in increased muscle strength in the upper and lower limbs, indicating systemic rather than site-specific effects as compared to BP. Based on these findings, Dmab might be favored over other osteoporosis treatments in patients with low BMD and poor muscle strength.
引用
- Rupp T, von Vopelius E, Strahl A, et al. Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study. Osteoporos Int. 2022. PMID: 35751664. doi:10.1007/s00198-022-06470-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。